Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
|Webinar:||“XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs”|
|Link:||Participants can register and access the webinar on the Investors section of Xenon’s website.|
|Format:||Questions may be submitted (via chat function) during the live webinar or submitted in advance via email.|
Sanjay J. Mathew, MD, Marjorie Bintliff Johnsonand Raleigh White Johnson, Jr. Vice Chair for Research Professor of Psychiatry & Behavioral Sciences Menninger Department of Psychiatry & Behavioral Sciencesat Baylor College of Medicine James W. Murrough, MD, PhD, Professor of Psychiatry and Neuroscience Director, Depression and Anxiety Center for Discoveryand Treatment Icahn School of Medicineat Mount Sinai Ian Mortimer, President and CEO, Xenon Pharmaceuticals(moderator) Chris Kenney, Chief Medical Officer, Xenon Pharmaceuticals Chris Von Seggern, Chief Commercial Officer, Xenon Pharmaceuticals
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
“Xenon” and the Xenon logo are registered trademarks or trademarks of
Source: Xenon Pharmaceuticals Inc.